Hydrasolve T2D Technology

Medality Medical’s HydraSolve T2D Visceral Fat Extraction System utilizes the unique, proprietary, and patented Targeted Cell Separation and Extraction Technology (TC-SET™), invented and developed by Medality Medical’s Founder and Chief Scientific Officer, Mark S. Andrew, MD. During the procedure, a pencil‐thin handheld surgical device streams a warmed, low-pressurized, and pulsed saline solution into the patient’s mesentery and works to selectively separate and extract the mesenteric visceral fat cells; while leaving non-fat cells unharmed. The mesenteric visceral fat cells are instantaneously exposed to the energized saline stream inside the opening of the handheld surgical device and are subdivided into small clusters that are immediately extracted out of the abdomen and into a collection canister. The handheld surgical instrument is blunt and rounded to avoid cutting any tissue and the warm (not hot) saline stream is not capable of burning tissue. It applies “just enough energy” to separate the mesenteric visceral fat cells and enable rapid extraction.

Visceral fat deposits are found mainly in the mesentery. It has been suggested that the mesentery deserves to be recognized as a new human organ, see video. Fat deposit in the mesentery also called mesenteric fat has been shown to play an important role in diseases such as type 2 diabetes, metabolic syndrome and cardiovascular disease.

Research Update

On February 5, 2019, the FDA approved Medality’s Investigational Device Exemption (“IDE”) application to undertake a human clinical trial for the extraction of excess mesenteric visceral fat to reverse T2D. On August 21, 2019 the University of Texas Health Sciences Center at San Antonio (“UTHSCSA”) Institutional Review Board (“IRB”) approved the commencement of patient screening for the clinical trial.

The clinical trial is conducted at The UT Health San Antonio.

The Principal Investigator is Ralph DeFronzo, MD, Professor of Medicine and Chief, Diabetes at UTHSCSA and Deputy Director, Texas Diabetes Institute. Dr. DeFronzo is a leading endocrinologist who has been globally recognized for his numerous research and clinical advances in type 2 diabetes. His research was instrumental in defining the role of insulin resistance in the development and progression of type 2 diabetes. The Sub-Investigator is Richard Peterson, MD, MPH, FACS, FASMBS Professor and Chief, UTHSCSA Bariatric and Metabolic Surgery and Director, University of Texas Medicine Center for Bariatric and Metabolic Surgery. Dr. Peterson was the lead bariatric surgeon on all of the surgeries performed in the primate study

This study will evaluate the safety and efficacy of the investigational use of the HydraSolve T2D™ System (previously FDA-cleared for liposuction and fat transfer) to perform a novel, minimally invasive laparoscopic and mini-laparotomy procedure to selectively remove intra-abdominal fat from the mesentery and to assess the resulting changes in blood glucose control, insulin sensitivity and body weight in 12 overweight/obese patients with type 2 diabetes. Excess intra-abdominal mesenteric fat has been directly linked to insulin resistance, an important precursor of type 2 diabetes. During the 12-month period post-procedure, the patients will be periodically monitored for improvements in blood glucose control, body weight, changes in fat deposits and overall metabolic health. Safety assessments and monitoring for adverse events will be performed, throughout.

To date, 11 patients have safely undergone the mesenteric visceral lipectomy (“MVL”) procedure using the HydraSolve T2D system. Results for the first seven patients clearly demonstrate the safety and a very promising trend in glycemic control.

The above video showcases:
  • Live Mesenteric Visceral Lipectomy procedure (“MVL”) performed by Dr. Peterson and Dr. Kempenich using HydraSolve T2D on an actual patient with type 2 diabetes.
  • How insulin resistance, obesity and visceral fat play an important part in the development and evolution of type 2 diabetes discussed by Dr. Defronzo, principal investigator of Medality’s FDA approved First-in-Human MVL Clinical Trial.
  • Early findings of the MVL clinical trial.

For more information, please visit our NIH Clinical Trial page.

Copyright 2024 Medality Medical, Inc. All rights reserved. | Privacy & Terms

Site design by Leftcoast Studios

Linkedin Twitter Youtube
Medality Medical Financial Conflict of Interest Policy
Medality Medical strives to create a research climate that promotes objectivity in research by establishing standards such that the design, conduct and reporting of Public Health Service (PHS, which includes NIH) funded research is free from bias resulting from financial conflict of interest (FCOI). This policy is applicable to each employee who is planning to or is participating in research activity that is either partially or wholly supported by PHS funds. Each such employee must:
  • disclose his or her significant financial interests (SFI) in non-Medality Medical entities that would appear to be related to the employee’s professional responsibilities on behalf of Medality Medical;
  • comply with an FCOI management plan, if an FCOI is identified; and
  • undergo FCOI training, at least once every four years.
Disclosure of SFI is essential for Medality Medical to determine if an FCOI exists, and in cases of FCOI determine how it will be managed and reported in full compliance with government regulation.